als 1

ALS-1 is an acid-Liable surfactant.This compound is unstable in powder form and other related salt forms are recommended.

Allitinib (AST-1306) (AST-1306) has anti-cancer activity,and it is an irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. [1]

GDC-0134, a dual leucine zipper kinase (DLK) inhibitor, exhibits brain penetration properties. It inhibits DLK to prevent neuronal degeneration and block JNK activation, potentially treating amyotrophic lateral sclerosis (ALS). It has been assessed in a phase 1 study aimed at treating ALS patients.

SARM1-IN-5 (compound 1-23-a) is an inhibitor of SARM1, useful for researching diseases related to axonal degeneration, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).

RNA binder 1 (Compound 4b) is an RNA-binding agent capable of crossing the blood-brain barrier. It selectively binds to the G-quadruplex structure of the G4C2 repeat sequence RNA of the C9orf72 gene. This compound significantly reduces levels of the toxic polypeptides poly(GA) and poly(GP) in cells derived from amyotrophic lateral sclerosis (ALS) patients, while it has no significant impact on the antisense polypeptide poly(PR), demonstrating selectivity for sense RNA. RNA binder 1 is useful for studying ALS and frontotemporal dementia (FTD).

Betulinic acid (ALS-357) is a pentacyclic lupane-type triterpene derivative of betulin (isolated from the bark of Betula alba, the common white birch) which has antiretroviral, antimalarial, and anti-inflammatory properties, as well as a more recently discovered potential as an anticancer agent, by inhibition of topoisomerase.

1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-PC is a phospholipid in biological membranes containing stearic acid and docosahexaenoic acid at the sn-1 and sn-2 positions, respectively. It has been used to study the organization and dynamics of lipid membranes. In the superoxide dismutase 1 mutant transgenic mouse model of amyotrophic lateral sclerosis (ALS) 1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-PC levels decrease in the anterior horn of L5 in late stages of the disease.1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-PC can be used to study biological membranes.

NF-κΒ Activator 2 is a potent, orally active compound that efficiently activates NF-κB with an EC50 value of 1.58 μM. By enhancing NF-κB expression and activation, it induces SOD 2 synthesis, rendering it useful for amyotrophic lateral sclerosis (ALS) research [1].

SOD1-Derlin-1 inhibitor 56-59 is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor 56-59 is potential in Amyotrophic lateral sclerosis (ALS) research.

C-ABL-IN-2 is a highly effective inhibitor of the c-Abl protein, which plays a significant role in the development of several diseases, including cancer. This compound exhibits promise for investigating neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), as well as cancer. (Source: WO2020260871A1, compound 25) [1].

c-ABL-IN-3, a highly effective c-Abl inhibitor, exhibits promising potential for studying neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), as well as cancer [1]. The activation of c-Abl has been strongly implicated in a range of diseases, notably cancer [1]. It offers valuable opportunities for research in these fields [1].

CLR01 is a molecular tweezer. CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy. CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS. CLR01 inhibits Ebola and Zika virus infection. CLR01 Stabilizes a Disordered Protein-Protein Interface. CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.

Sotuletinib hydrochloride (BLZ945 HCl) is a selective, brain-penetrant CSF-1R (c-Fms) inhibitor (IC50=1 nM), exhibiting 1000-fold greater selectivity than other receptor tyrosine kinase homologues. It elevates liver enzymes and induces Kupffer cell depletion, making it suitable for studying amyotrophic lateral sclerosis (ALS) and metastatic triple-negative breast cancer (TNBC).

NUCC-0000323 is a potent inhibitor of superoxide dismutase 1 (SOD1), effectively suppressing SOD1 expression. This compound has applications in amyotrophic lateral sclerosis (ALS) research.

Chrexanthomycin C, an orally active marine-derived natural product, exhibits significant bioactivities and shows a binding affinity for DNA [(G4C2)4 G4] with a dissociation constant (Kd) of 2.8 mM. This compound holds potential for neurodegenerative disease research, including amyotrophic lateral sclerosis (ALS) [1].

Proteasome-activating peptide 1 TFA is a potent activator of the proteasome, enhancing chymotrypsin-like proteasomal catalytic activity and increasing proteolytic rates both in vitro and in culture. It also inhibits protein aggregation in cellular models of amyotrophic lateral sclerosis (ALS) [1].

TRAF6 peptide, a specific TRAF6-p62 inhibitor, effectively inhibits NGF-dependent TrkA ubiquitination, showcasing strong research potential for neurological conditions including Alzheimer's disease (AD), Parkinson's, ALS, head trauma, epilepsy, and stroke [1].

TRAF6 peptide TFA, a specific inhibitor of the TRAF6-p62 interaction, significantly inhibits NGF-dependent ubiquitination of TrkA. This peptide demonstrates promising research applications in various neurological disorders, including Alzheimer's disease (AD), Parkinson's, ALS, head trauma, epilepsy, and stroke [1].

Sotuletinib (BLZ945) dihydrochloride is an orally administered, blood-brain barrier-permeable CSF1-R inhibitor with an IC50 of 1 nM, promoting apoptosis in tumor cells and significantly restricting tumor growth in murine models, thereby proving useful in cancer and amyotrophic lateral sclerosis (ALS) studies [1].

Foramsulfuron is a potent ALS (acetolactate synthase) inhibitor and sulfonylurea post-emergence herbicide that inhibits plant growth by blocking branched-chain amino acid biosynthesis, primarily targeting grass and broadleaf weeds in corn fields.

Proteasome-activating peptide 1 enhances chymotrypsin-like proteasomal catalytic activity, boosting proteolytic rates both in vitro and within cultured cells. Additionally, it inhibits protein aggregation in a cellular model of amyotrophic lateral sclerosis [1].

Ozanezumab (GSK1223249) is a monoclonal antibody targeting Nogo-A (neurite outgrowth inhibitor A). It is utilized in research related to amyotrophic lateral sclerosis (ALS) and multiple sclerosis [1].

Brassicanate A sulfoxide, isolated from Brassica oleracea [1], exhibits herbicidal properties by inhibiting the biosynthesis of essential amino acids in plants. It operates by binding to key enzymes such as dihydroxyacid dehydratase (DHAD), hydroxymethylpyruvate dioxygenase (HPPD), acetolactate synthase (ALS), PYL family proteins, and transport inhibitor response 1 (TIR1), thereby reducing their enzymatic activity.

C175-0062, a monoamine oxidase B (MAO-B) inhibitor, is applicable in research focused on neurodegenerative disorders such as Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS) [1].